# Yingsheng Biology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/yingsheng-biology

- Industry: Medical Devices & Equipment
- Headquarters: Jinan, China
- Website: www.ivdys.com
- Latest round: Series C (Mar 29, 2022)
- Investors on record: 12

## About

Based in Ji'nan, China and established in 2009, Yingsheng Biology is a biotechnology enterprise that focuses on medical testing research and development, equipment production and sales. The company has built a gene detection platform and mass spectrometry detection platform around metabonomics and genomics. The company has obtained more than 20 national patents and 6 software copyrights. Meanwhile, the company cooperates with companies such as Thermo Fisher of the United States, Hamilton of Switzerland, and Biotage of Sweden. They have built a platform technology development and achievement transformation center for mass spectrometry, molecule, and pathology, such as Yingsheng-Thermo Fisher Scientific Mass Spectrometry Localization Production Center, Yingsheng-Thermo Fisher Scientific International R&D and Transformation Center. In 2020, the company developed the new crown detection reagent. In 2019, the company established strategic cooperation with Thermo Fisher.

The company's main products are mass spectrometric detection instruments and diagnostic reagents, including high performance liquid chromatography-tandem mass spectrometry detection system, inductively coupled plasma mass spectrometer, mass spectrometry automatic intelligent processing platform, screening reagents for 48 genetic metabolic diseases of newborns. Besides, the company also provides third-party genetic testing and mass spectrometer detection services.

The company's revenue is generated by providing mass spectrometric detection instruments, diagnostic reagents and medical testing services.

In 2022, The company plans to achieve an Initial Public Offering.

## Funding rounds

- Series C, Mar 29, 2022 — China International Capital Corporation, China Taiping Insurance Group, YuanBio Venture, Sunz Fund, CD Capital, Far East Horizon, GL Ventures, HM Capital, Jingming Capital
- Series B, Nov 12, 2020 — YuanBio Venture, CD Capital, Riverhead Capital, Qianhai Ark Capital, GL Ventures
- Series C, Jun 4, 2019 — Xiamen C&D Group, YuanBio Venture
- Series A, Feb 24, 2016 — Sunz Fund

## Investors

- Sunz Fund (https://capitalatlas.ai/funds/sunz-fund) — Series A, Series C
- Xiamen C&D Group — Series C
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series C, Series B
- CD Capital — Series B, Series C
- Riverhead Capital (https://capitalatlas.ai/funds/riverhead-capital) — Series B
- Qianhai Ark Capital (https://capitalatlas.ai/funds/qianhai-ark-capital) — Series B
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series B, Series C
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series C
- China Taiping Insurance Group — Series C
- Far East Horizon — Series C
- HM Capital (https://capitalatlas.ai/funds/hm-capital) — Series C
- Jingming Capital (https://capitalatlas.ai/funds/jingming-capital) — Series C